1. Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study
- Author
-
Ng Wing Tin Sophie, Martin-Duverneuil Nadine, Idbaih Ahmed, Garel Catherine, Ribeiro Maria, Parker Judith, Defachelles Anne-Sophie, Lambilliotte Anne, Barkaoui Mohamed, Munzer Martine, Gardembas Martine, Sibilia Jean, Lutz Patrick, Fior Renato, Polak Michel, Robert Alain, Aumaitre Olivier, Plantaz Dominique, Armari-Alla Corinne, Genereau Thierry, Berard Perrine, Talom Ghislain, Pennaforte Jean-Loup, Le Pointe Hubert, Barthez Marie-Anne, Couillault Gérard, Haroche Julien, Mokhtari Karima, Donadieu Jean, and Hoang-Xuan Khê
- Subjects
Medicine - Abstract
Abstract Background Vinblastine (VBL) is the standard treatment for systemic Langerhans cell histiocytosis (LCH), but little is known about its efficacy in central nervous system (CNS) mass lesions. Methods A retrospective chart review was conducted. Twenty patients from the French LCH Study Group register met the inclusion criteria. In brief, they had CNS mass lesions, had been treated with VBL, and were evaluable for radiologic response. Results The median age at diagnosis of LCH was 11.5 years (range: 1-50). Intravenous VBL 6 mg/m2 was given in a 6-week induction treatment, followed by a maintenance treatment. The median total duration was 12 months (range: 3-30). Eleven patients received steroids concomitantly. Fifteen patients achieved an objective response; five had a complete response (CR: 25%), ten had a partial response (PR: 50%), four had stable disease (SD: 20%) and one patient progressed (PD: 5%). Of interest, four out of the six patients who received VBL without concomitant steroids achieved an objective response. With a median follow-up of 6.8 years, the 5-year event-free and overall survival was 61% and 84%, respectively. VBL was well-tolerated and there were no patient withdrawals due to adverse events. Conclusion VBL, with or without steroids, could potentially be a useful therapeutic option in LCH with CNS mass lesions, especially for those with inoperable lesions or multiple lesions. Prospective clinical trials are warranted for the evaluation of VBL in this indication.
- Published
- 2011
- Full Text
- View/download PDF